U.S. FDA approves Amylyx ALS drug

Summary by Ground News

The FDA has approved an Amylyx Pharmaceuticals drug for amyotrophic lateral sclerosis (ALS) Relyvrio is a combination of two compounds, tauroursodeoxycholic acid and sodium phenylbutyrate, which together are intended to lead to longer survival of neurons. No serious adverse events were reported from the study.

2 months ago·Washington, United States

News Articles

More Filters

All

Left

Center

Right

Reuters

U.S. FDA approves Amylyx ALS drug

The U.S. Food and Drug Administration on Thursday approved Amylyx Pharmaceuticals Inc's (AMLX.O) drug for slowing progression of ALS, or amyotrophic lateral sclerosis, and potentially delaying death.

2 months ago·United Kingdom

Read Full Article

CTV News

ALS drug wins U.S. FDA approval despite questionable data

A much-debated drug for Lou Gehrig's disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.

2 months ago·Toronto, Canada

Read Full Article

Associated Press News

ALS drug wins FDA approval despite questionable data

U.S. health officials have approved a much-debated drug to treat the deadly illness known as Lou Gehrig's disease. The approval Thursday follows an intense lobbying campaign by patients and advocates,

2 months ago·United States

Read Full Article

abc News

ALS drug wins FDA approval despite questionable data

U.S. health officials have approved a much-debated drug to treat the deadly illness known as Lou Gehrig's disease

2 months ago·United States

Read Full Article

CNN

ALS drug gets FDA approval despite uncertainty about effectiveness

A new treatment for amyotrophic lateral sclerosis, or ALS, has been approved by the US Food and Drug Administration.

2 months ago·Atlanta, United States

Read Full Article

New York Times

F.D.A. Approves A.L.S. Treatment Despite Questions About Effectiveness

The drug is safe, and one trial found it may extend survival and slow paralysis in functions like muscle control and speaking. A larger trial will be completed in 2024.

2 months ago·New York, United States

Read Full Article